Q4/2024 12/31/2024 EPS -0.650 ZacksConsensus -0.870 ActVsEst 0.220 - Beat
Inovio Pharmaceuticals, Inc. (INO)
NASDAQ:AMEX Investor Relations:
ir.inovio.com/investors/default.aspx
Company Research
Source: Wall Street Horizon
Impact Snapshot
Event Time:
INO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
INO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
INO alerts
High impacting Inovio Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
INO
News
- Inovio Pharmaceuticals (NASDAQ:INO) had its "sell (d-)" rating reaffirmed by analysts at <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>.MarketBeat
- INOVIO to Participate in December Investor ConferencesPR Newswire
- Individual investors invested in Inovio Pharmaceuticals, Inc. (NASDAQ:INO) lost 13% last week, institutions remained on the sidelines [Yahoo! Finance]Yahoo! Finance
- Inovio Pharmaceuticals (NASDAQ:INO) had its "overweight" rating reaffirmed by analysts at UBS Group AG.MarketBeat
- Inovio Pharmaceuticals (NASDAQ:INO) had its "overweight" rating reaffirmed by analysts at Piper Sandler.MarketBeat
INO
Earnings
- 11/10/25 - Miss
INO
Sec Filings
- 11/14/25 - Form SCHEDULE
- 11/14/25 - Form SCHEDULE
- 11/14/25 - Form SCHEDULE
- INO's page on the SEC website